89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study

D. G.J. Linders*, M. M. Deken, M. A. van Dam, M. N.J.M. Wasser, E. M.C. Voormolen, J. R. Kroep, G. A.M.S. van Dongen, D. Vugts, H. M. Oosterkamp, M. E. Straver, C. J.H. van de Velde, D. Cohen, P. Dibbets-Schneider, F. H.P. van Velden, L. M. Pereira Arias-Bouda, A. L. Vahrmeijer, G. J. Liefers, L. F. de Geus-Oei, D. E. Hilling*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Scopus)
58 Downloads (Pure)

Fingerprint

Dive into the research topics of '89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science